Beta Drugs Ltd
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]
- Market Cap ₹ 1,256 Cr.
- Current Price ₹ 1,306
- High / Low ₹ 1,595 / 660
- Stock P/E 36.1
- Book Value ₹ 148
- Dividend Yield 0.00 %
- ROCE 33.9 %
- ROE 28.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has delivered good profit growth of 35.4% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.8%
Cons
- Stock is trading at 8.85 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|
51 | 66 | 91 | 116 | 184 | 227 | 256 | |
41 | 54 | 73 | 91 | 141 | 174 | 197 | |
Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 59 |
OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 23% |
0 | 0 | 0 | 0 | 1 | 1 | 1 | |
Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 |
Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 11 |
Profit before tax | 7 | 8 | 12 | 16 | 34 | 41 | 46 |
Tax % | 1% | -2% | 21% | 27% | 28% | 25% | |
7 | 8 | 9 | 12 | 25 | 31 | 35 | |
EPS in Rs | 7.82 | 9.30 | 9.80 | 12.19 | 25.83 | 31.95 | 36.15 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | 36% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | 48% |
TTM: | 20% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 62% |
3 Years: | 89% |
1 Year: | 67% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 25% |
3 Years: | 27% |
Last Year: | 29% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|
Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 132 |
8 | 20 | 23 | 17 | 21 | 20 | 15 | |
9 | 22 | 28 | 31 | 45 | 55 | 80 | |
Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 237 |
13 | 18 | 44 | 40 | 55 | 63 | 64 | |
CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
35 | 50 | 63 | 74 | 102 | 135 | 173 | |
Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 237 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
17 | 0 | 8 | 19 | 30 | 23 | |
-11 | -21 | -15 | -6 | -22 | -19 | |
5 | 12 | 9 | -8 | -1 | -2 | |
Net Cash Flow | 12 | -9 | 2 | 5 | 7 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 |
Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 |
Days Payable | 81 | 143 | 119 | 127 | 123 | 139 |
Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 |
Working Capital Days | 75 | 100 | 95 | 88 | 70 | 88 |
ROCE % | 18% | 21% | 22% | 36% | 34% |
Product Portfolio
The company's product portfolio includes 63 molecules and ~110 SKUs primarily in the oncology segment in the areas of solid tumor, Hematology, and Supportive care. [1]